Laurus Labs IPO
Laurus Labs IPO — date, price band, lot size & details 2016
Laurus Labs listed on 19 Dec 2016 at ₹489.9, 14.5% above the ₹428 issue price.
Laurus Labs is a Hyderabad based maker of generic APIs for antiretrovirals and Hepatitis C, along with oncology and other APIs. Its total income was Rs 1,788.42 crore in FY2016.
Stock price
Laurus Labs is listed — here is the live share price.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Timetable
Key dates from opening to listing. Today is 14 November.
- Open 06 Dec 2016
- Close 08 Dec 2016
- Allotment 14 Dec 2016
- Refund/credit 15 Dec 2016
- Listing 19 Dec 2016
Issue summary
The terms of the offer, as filed.
| IPO Dates | 6 to 8 Dec, 2016 |
|---|---|
| Price Band | ₹426 – ₹428 |
| Face Value | ₹10 |
| Lot Size | 35 Shares |
| Issue Size | ₹1330.51 Cr |
| Sale Type | Fresh capital cum OFS |
| Listing On | BSE, NSE |
| Employee Discount | Rs 40.00 per share |
| Registrar | KFin Technologies Limited |
| Min Investment | ₹ 14,980 |
Share of the offer set aside for each investor category, as stated in the offer document.
What will it cost me?
Bidding is in multiples of 35 shares at the ₹428 cut-off. Drag to size your application.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 35 | ₹14,980 |
| Retail (max) | 13 | 455 | ₹1,94,740 |
| S-HNI (min) | 14 | 490 | ₹2,09,720 |
| S-HNI (max) | 66 | 2,310 | ₹9,88,680 |
| B-HNI (min) | 67 | 2,345 | ₹10,03,660 |
Strengths & risks
Drawn from the offer document — the case for and against, side by side.
Strengths · 4
- 01Total income rose from Rs 1,168.53 crore in FY2014 to Rs 1,788.42 crore in FY2016.
- 02Profit after tax rose from Rs 73.52 crore in FY2015 to Rs 143.57 crore in FY2016.
- 03EBITDA rose from Rs 217.68 crore in FY2014 to Rs 389.60 crore in FY2016.
- 04Rs 226.29 crore of the issue was for prepaying term loans.
Risks · 5
- 01Total borrowing was Rs 845.43 crore on 30 June 2016, close to its net worth.
- 02Profit after tax fell from Rs 97.22 crore in FY2014 to Rs 73.52 crore in FY2015.
- 03It depends heavily on antiretroviral APIs, whose prices are under pressure; total assets were Rs 2,594.18 crore.
- 04Rs 1,030.80 crore of the Rs 1,330.51 crore issue went to selling shareholders.
- 05The promoters held only 32.82% before the issue and 30.66% after it.
Three years of numbers
All figures in ₹ crore, as reported in the Laurus Labs offer document.
| Metric | 30 Jun 2016 | 31 Mar 2016 | 31 Mar 2015 | 31 Mar 2014 |
|---|---|---|---|---|
| Assets | 2,594.18 | 2,308.35 | 1,892.55 | 1,273.06 |
| Total Income | 939.68 | 1,788.42 | 1,360.38 | 1,168.53 |
| Profit After Tax | 82.01 | 143.57 | 73.52 | 97.22 |
| EBITDA | 213.63 | 389.60 | 239.41 | 217.68 |
| NET Worth | 951.38 | 867.40 | 727.27 | 358.42 |
| Reserves and Surplus | 852.63 | 785.02 | 645.14 | 280.58 |
| Total Borrowing | 845.43 | 928.85 | 735.31 | 500.36 |
See how this IPO compares — view listing performance of all mainboard IPOs.
Where the money goes
₹286.71 Cr of the issue is earmarked to named objects.
Laurus Labs IPO Anchor Investors
25 anchor investors across 15 fund houses committed ₹395.41 Cr a day before the issue opened.
Anchor investors bid a day before the issue opens and are locked in after allotment, so a book weighted towards domestic mutual funds is generally read as a stronger signal than one filled by short-horizon funds. Browse every anchor investor scheme or fund house we track.
About the company
It makes generic active pharmaceutical ingredients for antiretrovirals and Hepatitis C, and APIs in oncology and other therapeutic areas.
It operates across four business lines, starting with generic APIs.
The IPO was Rs 1,330.51 crore, with Rs 299.71 crore of fresh issue and Rs 1,030.80 crore of offer for sale, at Rs 428, the top of the Rs 426 to Rs 428 band. Most of the fresh money was for prepaying term loans.
Interested in this IPO? Check the live subscription status or browse all upcoming mainboard IPOs.
The bankers & the filings
Who is running the book, and the documents this page is built from.
Laurus Labs IPO Documents
Read the filings this page is built from.
Lead Manager Track Record
How the book-running lead managers on this issue have priced their past IPOs, measured on listing day.
SBI Capital Markets Ltd.
141 issues handledBest listing: Bajaj Housing Finance (+114.3%). Weakest: ICICI Securities (-16.3%).
Kotak Mahindra Capital Company Limited
204 issues handledBest listing: Premier Energies (+120.0%). Weakest: Puravankara Projects (-22.5%).
Jefferies India Private Limited
41 issues handledBest listing: Nazara Technologies (+80.7%). Weakest: Turtlemint Fintech Solutions (-10.4%).
Citigroup Global Markets India Pvt. Ltd
74 issues handledBest listing: Tata Technologies (+140.0%). Weakest: Puravankara Projects (-22.5%).
Listing gain compares the listing-day opening price with the issue price, using the IPOs on IPO Guru that this lead manager has taken to market. A strong record reflects how the banker has priced past issues — it is not a forecast for this one. See every issue they have handled on the lead managers page.
Company contact
Frequently asked
What is the GMP of Laurus Labs?
The current Grey Market Premium is ₹0.
What is the Laurus Labs IPO price band?
₹426 to ₹428, on a face value of ₹10.
When is the allotment?
The basis of allotment is 14 December 2016, with listing on 19 December 2016.
How do I check allotment status?
On the IPO Guru allotment page or on the registrar's site — KFin Technologies Limited.
Every number here traces back to a filing.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Every number on this page is sourced from the RHP, BSE & NSE.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
